Edgewise Therapeutics, Inc. (EWTX)Â
NASDAQ$22.11-0.69 (-3.03%)
Market Cap
$2.17B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
588 of 919
Rank in Industry
339 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
EWTX Insider Trading Activity
EWTX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $14,567,127 | 22 | 100 |
Related Transactions
| KOCH KEVIN | President and CEO | 0 | $0 | 4 | $349,920 | $-349,920 |
| Semigran Marc | Chief Development Officer | 0 | $0 | 1 | $881,915 | $-881,915 |
| Donovan Joanne M. | CMO | 0 | $0 | 3 | $962,887 | $-962,887 |
| Derakhshan Behrad | Chief Business Officer | 0 | $0 | 3 | $1.55M | $-1.55M |
| MOORE JOHN R | General Counsel | 0 | $0 | 3 | $2.03M | $-2.03M |
| Carruthers R Michael | Chief Financial Officer | 0 | $0 | 2 | $3.61M | $-3.61M |
| Russell Alan J | Chief Scientific Officer | 0 | $0 | 6 | $5.17M | $-5.17M |
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Insider Activity of Edgewise Therapeutics, Inc.
Over the last 12 months, insiders at Edgewise Therapeutics, Inc. have bought $0 and sold $14.57M worth of Edgewise Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Edgewise Therapeutics, Inc. have bought $30.86M and sold $7.36M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 454,545 shares for transaction amount of $5M was made by Thompson Peter A. () on 2024‑01‑23.
List of Insider Buy and Sell Transactions, Edgewise Therapeutics, Inc.
| 2025-03-07 | Sale | Russell Alan J | Chief Scientific Officer | 200 0.0002% | $30.02 | $6,004 | -9.91% | |
| 2025-03-07 | Sale | KOCH KEVIN | President and CEO | 100 0.0001% | $30.00 | $3,000 | -9.91% | |
| 2025-02-06 | Sale | Russell Alan J | Chief Scientific Officer | 1,200 0.0013% | $30.13 | $36,153 | -9.25% | |
| 2025-02-06 | Sale | KOCH KEVIN | President and CEO | 900 0.001% | $31.13 | $28,018 | -9.25% | |
| 2025-02-05 | Sale | Derakhshan Behrad | Chief Business Officer | 10,000 0.0108% | $30.03 | $300,300 | -13.25% | |
| 2025-02-05 | Sale | Russell Alan J | Chief Scientific Officer | 8,015 0.0086% | $30.02 | $240,623 | -13.25% | |
| 2025-02-05 | Sale | KOCH KEVIN | President and CEO | 8,636 0.0093% | $30.03 | $259,298 | -13.25% | |
| 2025-01-28 | Sale | Donovan Joanne M. | CMO | 25,000 0.0263% | $27.63 | $690,658 | -5.86% | |
| 2024-12-30 | Sale | Russell Alan J | Chief Scientific Officer | 100,000 0.1006% | $27.37 | $2.74M | -2.33% | |
| 2024-12-24 | Sale | Semigran Marc | Chief Development Officer | 29,709 0.0314% | $29.69 | $881,915 | -10.38% | |
| 2024-09-23 | Sale | MOORE JOHN R | General Counsel | 20,922 0.0233% | $27.63 | $578,064 | +6.46% | |
| 2024-09-20 | Sale | Derakhshan Behrad | Chief Business Officer | 42,068 0.046% | $29.03 | $1.22M | -0.32% | |
| 2024-09-20 | Sale | Donovan Joanne M. | CMO | 7,162 0.0076% | $28.29 | $202,603 | -0.32% | |
| 2024-09-20 | Sale | Russell Alan J | Chief Scientific Officer | 75,000 0.0799% | $28.27 | $2.12M | -0.32% | |
| 2024-09-20 | Sale | Carruthers R Michael | Chief Financial Officer | 125,092 0.1348% | $28.57 | $3.57M | -0.32% | |
| 2024-09-20 | Sale | MOORE JOHN R | General Counsel | 50,000 0.0535% | $28.37 | $1.42M | -0.32% | |
| 2024-05-02 | Sale | Carruthers R Michael | Chief Financial Officer | 2,157 0.0023% | $18.91 | $40,789 | +32.92% | |
| 2024-05-02 | Sale | Donovan Joanne M. | CMO | 3,682 0.0039% | $18.91 | $69,627 | +32.92% | |
| 2024-05-02 | Sale | KOCH KEVIN | President and CEO | 3,152 0.0033% | $18.91 | $59,604 | +32.92% | |
| 2024-05-02 | Sale | Derakhshan Behrad | Chief Business Officer | 1,718 0.0018% | $18.91 | $32,487 | +32.92% |
Total: 85
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Derakhshan Behrad | Chief Business Officer | 16837 0.0177% | $383,883.60 | 0 | 7 | |
| Donovan Joanne M. | CMO | 16358 0.0172% | $372,962.40 | 0 | 4 | |
| Russell Alan J | Chief Scientific Officer | 14863 0.0156% | $338,876.40 | 0 | 33 | |
| KOCH KEVIN | President and CEO | 14478 0.0152% | $330,098.40 | 0 | 5 | |
| Carruthers R Michael | Chief Financial Officer | 6904 0.0073% | $157,411.20 | 0 | 4 | |
| Semigran Marc | Chief Development Officer | 6716 0.0071% | $153,124.80 | 0 | 1 | |
| MOORE JOHN R | General Counsel | 3252 0.0034% | $74,145.60 | 0 | 17 | |
| ORBIMED ADVISORS LLC | 14436497 15.1635% | $329.15M | 4 | 0 | +0.53% | |
| Thompson Peter A. | 14436497 15.1635% | $329.15M | 4 | 0 | +0.53% | |
| OrbiMed Genesis GP LLC | 13497456 14.1772% | $307.74M | 1 | 0 | +30.03% | |
| Novo Holdings A/S | 10 percent owner | 6071703 6.3775% | $138.43M | 2 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 3933137 4.1312% | $89.68M | 1 | 0 | <0.0001% |
| ROOT JONATHAN D | director | 15625 0.0164% | $356,250.00 | 1 | 0 | <0.0001% |
| Fox Jonathan C | director | 10857 0.0114% | $247,539.60 | 1 | 0 | +90.07% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.11B | |
$1,376,668 | 53 | 18.46% | $2.4B | |
$224,319,161 | 41 | 27.46% | $2.31B | |
$62,927,079 | 29 | 14.02% | $2.3B | |
$150,253,463 | 26 | -52.83% | $2.1B | |
$1,801,511 | 23 | 18.58% | $2.02B | |
Edgewise Therapeutics, Inc. (EWTX) | $92,580,864 | 14 | -1.28% | $2.17B |
$75,296,816 | 12 | 37.23% | $2.07B | |
$137,013,690 | 11 | 26.62% | $2.03B | |
$1,248,715 | 10 | 5.66% | $2.63B | |
$117,959,652 | 9 | -12.47% | $2.51B | |
$55,713,031 | 8 | -0.36% | $2.34B | |
$32,575,266 | 8 | 37.03% | $2.14B | |
$25,073,947 | 7 | -5.99% | $1.89B | |
$103,599,972 | 2 | -36.81% | $2.58B | |
$7,600,000 | 1 | -4.05% | $2.12B | |
$95,000 | 1 | -0.78% | $2.57B | |
$49,999,992 | 1 | 50.02% | $2.37B | |
$9,900,000 | 1 | -7.19% | $2.05B |
EWTX Institutional Investors: Active Positions
| Increased Positions | 119 | +65.03% | 10M | +10.16% |
| Decreased Positions | 81 | -44.26% | 12M | -12.09% |
| New Positions | 48 | New | 4M | New |
| Sold Out Positions | 20 | Sold Out | 5M | Sold Out |
| Total Postitions | 221 | +20.77% | 99M | -1.92% |
EWTX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Orbimed Advisors Llc | $354,663.00 | 15.81% | 15.02M | 0 | 0% | 2024-12-31 |
| Ra Capital Management, L.P. | $210,344.00 | 9.38% | 8.91M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $152,970.00 | 6.82% | 6.48M | +85,448 | +1.34% | 2024-12-31 |
| Baker Bros. Advisors Lp | $145,342.00 | 6.48% | 6.16M | +315,881 | +5.41% | 2024-12-31 |
| Novo Holdings A/S | $118,050.00 | 5.26% | 5M | -549,900 | -9.91% | 2024-12-31 |
| Janus Henderson Group Plc | $117,671.00 | 5.25% | 4.98M | +425,421 | +9.33% | 2024-12-31 |
| Paradigm Biocapital Advisors Lp | $106,102.00 | 4.73% | 4.49M | +2M | +61.12% | 2024-12-31 |
| Vanguard Group Inc | $105,462.00 | 4.7% | 4.47M | -49,214 | -1.09% | 2024-12-31 |
| Cormorant Asset Management, Lp | $80,428.00 | 3.59% | 3.41M | 0 | 0% | 2024-12-31 |
| Perceptive Advisors Llc | $63,406.00 | 2.83% | 2.69M | +355,243 | +15.24% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.